Bridgebio Pharma Inc   (BBIO)
Other Ticker:  
Price: $34.8700 $0.87 2.559%
Day's High: $35.03 Week Perf: -3 %
Day's Low: $ 33.66 30 Day Perf: -3.33 %
Volume (M): 1,147 52 Wk High: $ 44.32
Volume (M$): $ 40,006 52 Wk Avg: $25.34
Open: $33.79 52 Wk Low: $10.57

 Market Capitalization (Millions $) 5,695
 Shares Outstanding (Millions) 163
 Employees -
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -623
 Cash Flow (TTM) (Millions $) 38
 Capital Exp. (TTM) (Millions $) 2

Bridgebio Pharma Inc
BridgeBio Pharma Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing targeted therapies to treat genetic diseases. The company utilizes a diversified approach to drug development, targeting a range of diseases including oncology, cardiology, dermatology, neurology, and endocrinology. BridgeBio operates through a subsidiary model, with a portfolio of subsidiaries that are controlled by the company and dedicated to specific genetic diseases. The company aims to apply innovative science to address the unmet needs of patients with genetic diseases and bring transformative therapies to market.

   Company Address: 3160 Porter Drive Palo Alto 94304 CA
   Company Phone Number: 391-9740   Stock Exchange / Ticker: NASDAQ BBIO


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


BridgeBio Pharma and Kyowa Kirin Disrupt Skeletal Dysplasia Treatment Landscape in Japan with Exclusive License Partnership

Published Wed, Feb 7 2024 12:35 PM UTC

In a groundbreaking partnership, BridgeBio Pharma and Kyowa Kirin have joined forces to develop and commercialize infigratinib for the treatment of skeletal dysplasias in Japan. With an upfront payment of $100 million, this deal marks a significant development in the field of rare genetic disorders, with considerable implications for both companies involved.BridgeBio Pharma,...


BridgeBio Pharma Grants Inducement Stock Units to Drive Innovation and Growth within the Company

Published Tue, Feb 6 2024 12:31 PM UTC

As the biopharmaceutical industry continues to evolve, BridgeBio Pharma, Inc. stands out as a leader in genetic diseases and cancers. With recent announcements of inducement grants under Nasdaq Listing Rule 5635(c)(4), BridgeBio is actively attracting and retaining top talent to drive innovation and growth within the company.
On February 5, 2024, BridgeBio Pharma grante...

Licensing Agreement

BridgeBio Pharma's Acoramidis NDA for Transthyretin Amyloid Cardiomyopathy Accepted by FDA - A Promising Milestone

Published Mon, Feb 5 2024 12:30 PM UTC

In a significant development, BridgeBio Pharma recently announced the acceptance of the New Drug Application (NDA) for Acoramidis by the U.S. Food and Drug Administration (FDA). Acoramidis is a potential breakthrough treatment for patients suffering from Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a rare and life-threatening disease. This article aims to outline the esse...

Clinical Study

BridgeBio Pharma's Acoramidis shows remarkable potential in Japanese patients with Transthyretin Amyloid Cardiomyopathy: Phase 3 study reports no mortality at 30 months

Published Fri, Feb 2 2024 12:01 PM UTC

In a groundbreaking development in the field of rare diseases, BridgeBio Pharma recently announced positive results from a single-arm Phase 3 study of Acoramidis in Japanese patients suffering from Transthyretin Amyloid Cardiomyopathy (ATTR-CM). The study, conducted by BridgeBio's licensing partners, Alexion and AstraZeneca Rare Disease, showcased remarkable consistency with...

Financing Agreement

BridgeBio Pharma Receives $1.25 Billion Funding and Grants Inducement Stock Units to Drive Genetic Medicine Development

Published Thu, Jan 18 2024 12:00 PM UTC

BridgeBio Pharma Secures Funding and Grants Inducement Stock Units to Expand Workforce
BridgeBio Pharma, a leading biopharmaceutical company, recently announced a significant development in its efforts to advance the treatment of genetic diseases and cancers. The company has secured up to $1.25 billion in capital from Blue Owl and CPP Investments, which will be used to ...


Bridgebio Pharma Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com